Table 2.
Baseline characteristics
| Characteristics | Values |
|---|---|
| Age, M (Q1, Q3), y | 72 (68, 79) |
| Height, M (Q1, Q3), m | 1.66 (1.61, 1.70) |
| Weight, Mean ± SD, kg | 64.94 ± 8.77 |
| BMI, Mean ± SD, kg/m2 | 23.71 ± 2.76 |
| PSA, M (Q1, Q3), ng/ml | 25.90 (12.00, 84.50) |
| SFT, M (Q1, Q3), mm | 29.85 (22.24, 38.23) |
| PPFT, M (Q1, Q3), mm | 6.90 (3.80, 9.67) |
| PPFA, M (Q1, Q3), cm2 | 17.78 (13.10, 25.21) |
| PA, M (Q1, Q3), cm2 | 13.52 (10.76, 17.36) |
| PPFV, M (Q1, Q3), cm3 | 48.76 (36.36, 63.52) |
| PV, M (Q1, Q3), ml | 49.73 (36.11, 67.25) |
| PPFA/PA, M (Q1, Q3), % | 133.18 (83.24, 191.67) |
| PPFV/PV, M (Q1, Q3), % | 99.43 (73.83, 116.49) |
| PSAD, M (Q1, Q3), ng/ml2, % | 58.53 (24.04, 153.14) |
| PSA×PPFA/PA, M (Q1, Q3), ng/ml | 36.27 (13.69, 112.88) |
| PI-RADS, n (%) | |
| 2 | 3 (1.4) |
| 3 | 28 (13.0) |
| 4 | 35 (16.3) |
| 5 | 149 (69.3) |
| Gleason score, n (%) | |
| ≤ 6 | 31(14.4) |
| 3 + 4 | 32(14.9) |
| 4 + 3 | 39(18.1) |
| 8 | 57(26.5) |
| 9–10 | 56(26.1) |
SD, Mean ± Standard Deviation; M (Q1, Q3), Median (Interquartile Range, 25% and 75%); SFT, Subcutaneous fat thickness; PPFT, Periprostatic fat thickness; PPFA, Periprostatic fat tissue area; PA, Prostate area; PPFV, Periprostatic fat tissue volume; PV, Prostate volume; PSA, Prostate specific antigen; PSAD, Prostate specific antigen density; BMI, Body mass index